

October 2, 2025



Cocrystal Pharma to Present at Noble Capital Markets Emerging Growth Virtual Equity Conference

BOTHELL, Wash., Oct. 02, 2025 (GLOBE NEWSWIRE) -- [Cocrystal Pharma, Inc.](#) (Nasdaq: COCP) ("Cocrystal" or the "Company") announces that James Martin, CFO and co-CEO, will present a company overview at the Noble Capital Markets Emerging Growth Virtual Equity Conference on Thursday, October 9, 2025 at 12:00 pm Eastern time (9:00 a.m. Pacific time). The formal presentation will be followed by a hosted question-and-answer session with questions welcomed from the live virtual audience.

Those interested in viewing the live Cocrystal presentation can register for the event [here](#). A video webcast of the presentation will be available within 48 hours following the event on the Company's [website](#) and archived for 90 days.

Mr. Martin will be available throughout the conference for virtual one-on-one meetings with registered, qualified investors. Meetings can be scheduled by contacting Giorgia Pigato [here](#) at Noble Capital Markets.

About Noble Capital Markets, Inc.

[Noble Capital Markets](#) is a research-driven investment bank that has supported small and microcap companies since 1984. As a FINRA and SEC licensed broker dealer, Noble provides institutional-quality equity research, merchant and investment banking, and order execution services. In 2018, Noble launched [Channelchek](#)—an investor community dedicated exclusively to public small and micro-cap companies and their industries. Channelchek is the first service to offer investors free institutional-quality research without a subscription.

About Cocrystal Pharma, Inc.

Cocrystal Pharma, Inc. is a clinical-stage biotechnology company that addresses significant unmet needs by developing innovative antiviral treatments for challenging diseases including influenza, viral gastroenteritis, COVID, and hepatitis. Cocrystal employs unique structure-based technologies and Nobel Prize-winning expertise to create first- and best-in-class antiviral drugs.

Contact:

Alliance Advisors IR

Jody Cain

310-691-7100

jcain@allianceadvisors.com

###



Source: Cocrystal Pharma, Inc.